Jonathan P. Terdiman, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jonathan P. Terdiman, MD

Associate Clinical Professor, Department of Medicine (Gastroenterology), UCSF

Phone: (415) 502-4444 (appts)
Box 1623, UCSF
San Francisco, CA 94143-1623

UCSF Profiles | Physician Referral Directory

Cancer Center Membership

Associate Member » Cancer Genetics

Research Summary

Dr. Jonathan P. Terdiman is a Professor of Clinical Medicine and Surgery at UCSF. He earned his undergraduate degree from Princeton University in 1985 and his medical degree from the Columbia University College of Physicians and Surgeons in 1989. Dr. Terdiman completed his internal medicine residency and fellowships in both critical care medicine and gastroenterology at UCSF before joining the faculty in 1996. Dr. Terdiman currently serves as the Director of the Adult Gastroenterology Service, the Program Director of the Gastroenterology Fellowship Training Program, and Director of the Gastrointestinal Cancer Prevention Program at UCSF. Dr. Terdiman has been the recipient of numerous school-wide teaching awards and in 2013 Dr Terdiman was elected to the Department of Medicine’s Master Clinician Council. This is a rare and distinct honor and a testament to the high esteem in which Dr. Terdiman is held by his colleagues. Dr. Terdiman is considered by his peers and the community to be one of the leading practitioners of gastroenterology in the Bay area, and he serves as an invaluable resource to patients and referring providers alike. Dr. Terdiman has a reputation among his peers for taking on the most challenging cases and for his attention to detail and compassion.

Dr. Terdiman’s primary clinical and research activities are focused on the treatment of patients at high risk for gastrointestinal cancer and those with inflammatory bowel disease, though he cares for patients with a wide range of gastrointestinal diseases. He is engaged in research projects regarding how to assess and mitigate the risk of cancer among patients and families with a genetic predisposition to the disease. He also is actively engaged in projects assessing the safety and efficacy of new drugs in the treatment of inflammatory bowel disease, and recently he and his colleagues have embarked on an exciting series of studies examining the role of the microbiome in the etiology of IBD. The goal of these latter studies is to understand if manipulation of the microbiome be an important form of therapy for patients with IBD. Initial studies are focusing on the use of diet and fecal transfer to achieve these goals.

Dr Terdiman has served on the board of the Northern California Chapter of the Crohn’s and Colitis Foundation of America (CCFA) for many years, and was board president from 2010-2012. In 2012 the chapter named Dr. Terdiman as a CCFA Champion of Hope. Dr. Terdiman also is the lead author of the American Gastroenterological Association guidelines regarding the proper use of immune modulators and biological drugs in the treatment of Crohn’s disease. Dr. Terdiman is a past associate editor of the American Journal of Gastroenterology and he is a fellow of the American College of Gastroenterology and American College of Physicians.

Education

Princeton University, A.B., cum laude, 1985
Columbia University, College of Physicians and Surgeons, M.D., 1989


Professional Experience

  • 1989-1992
    Resident in Internal Medicine, University of California, San Francisco, San Francisco CA
  • 1992-1993
    Fellow in Critical Care Medicine, University of California, San Francisco, San Francisco, CA
  • 1993-1996
    Fellow in Gastroenterology, University of California, San Francisco, San Francisco, CA
  • 1996-2000
    Staff Physician, Department of Veterans Affairs Medical Center, San Francisco, CA
  • 1996-2002
    Assistant Clinical Professor of Medicine, University of California, San Francisco, San Francisco, CA
  • 1996-present
    Staff Physician, University of California, San Francisco Medical Center, San Francisco, CA
  • 1996-present
    Director of the Colorectal Cancer Prevention Program, UCSF, San Francisco, CA
  • 1998-present
    Clinical Director, Center for Inflammatory Bowel Disease, UCSF, San Francisco, CA
  • 1998-present
    Member, Cancer Center, University of California, San Francisco, San Francisco, CA
  • 1998-present
    Member, Gastrointestinal Oncology Section, American Gastroenterological Society, Bethesda, MD
  • 1999-present
    Member, Colorectal Cancer Initiative Team, American Cancer Society California Division, Oakland, CA
  • 2000-present
    Chair, Abstract Review Committee, GI Oncology Section, AGA, Bethesda, MD
  • 2001-present
    Co-Chair, Crohn's and Colitis Foundation, northern California Chapter, Medical Advisory Board
  • 2002-present
    Associate Professor of Clinical Medicine, University of California, San Francisco, San Francisco, CA
  • 2003-present
    Director, Gastroenterology Fellowship, University of California, San Francisco, San Francisco, CA
  • 2005-present
    Member, Academy of Medical Educators, University of California, San Francisco, SF, CA

Honors & Awards

  • 2000
    UCSF Medical School Class of 2002, Excellence in Small Group Instruction, recipient
  • 2002
    UCSF Medical School Class of 2004, Excellence in Small Group Instruction, recipient
  • 2004
    UCSF Medical School Class of 2006, Excellence in Small Group Instruction, recipient
  • 2005
    Excellence in Direct Teaching, recipient, UCSF Academy of Medical Educators

Selected Publications

  1. Kidambi TD, Lee R, Terdiman JP, Day L. Successful implementation of Lynch syndrome screening in a safety net institution. J Community Genet. 2016 Jul 2.
    View on PubMed
  2. Kidambi TD, Blanco A, Van Ziffle J, Terdiman JP. Constitutional MLH1 methylation presenting with colonic polyposis syndrome and not Lynch syndrome. Fam Cancer. 2016 Apr; 15(2):275-80.
    View on PubMed
  3. Guindalini RS, Win AK, Gulden C, Lindor NM, Newcomb PA, Haile RW, Raymond V, Stoffel E, Hall M, Llor X, Ukaegbu CI, Solomon I, Weitzel J, Kalady M, Blanco A, Terdiman J, Shuttlesworth GA, Lynch PM, Hampel H, Lynch HT, Jenkins MA, Olopade OI, Kupfer SS. Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch Syndrome. Gastroenterology. 2015 Nov; 149(6):1446-53.
    View on PubMed
  4. Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M, Win AK, Senter L, Lipkin SM, Stadler ZK, Macrae FA, Lynch HT, Weitzel JN, de la Chapelle A, Syngal S, Lynch P, Parry S, Jenkins MA, Gallinger S, Holter S, Aronson M, Newcomb PA, Burnett T, Le Marchand L, Pichurin P, Hampel H, Terdiman JP, Lu KH, Thibodeau S, Lindor NM. PMS2 monoallelic mutation carriers: the known unknown. Genet Med. 2016 Jan; 18(1):13-9.
    View on PubMed
  5. Kidambi TD, Terdiman JP. Screening for Lynch syndrome: it is time to shift the focus. Dig Dis Sci. 2015 Feb; 60(2):586-7.
    View on PubMed
  6. Lee JK, Terdiman JP, Corley DA. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 Jul 10; 371(2):186.
    View on PubMed
  7. Kidambi TD, Blanco A, Myers M, Conrad P, Loranger K, Terdiman JP. Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience. Dig Dis Sci. 2015 Aug; 60(8):2463-9.
    View on PubMed
  8. Walsh JM, Potter MB, Arora M, Gildegorin G, Terdiman J. A workplace colorectal cancer screening program in firefighters: lessons learned. Occup Med (Lond). 2014 Jun; 64(4):255-8.
    View on PubMed
  9. Shah S, Terdiman J, Gundling K, Mahadevan U. Immunoglobulin therapy for refractory Crohn's disease. Therap Adv Gastroenterol. 2014 Mar; 7(2):99-102.
    View on PubMed
  10. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-a biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013 Dec; 145(6):1459-63.
    View on PubMed
  11. Truta B, Li DX, Mahadevan U, Fisher ER, Chen YY, Grace K, Velayos F, Terdiman JP. Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis. Dig Dis Sci. 2014 Jan; 59(1):135-45.
    View on PubMed
  12. Yurgelun MB, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad P, Blanco A, Shannon KM, Chung DC, Terdiman J, Gruber SB, Garber JE, Syngal S, Stoffel EM. Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol. 2012 Dec; 127(3):544-51.
    View on PubMed
  13. Kuppermann M, Wang G, Wong S, Blanco A, Conrad P, Nakagawa S, Terdiman J, Ladabaum U. Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome. Cancer. 2013 Jan 1; 119(1):215-25.
    View on PubMed
  14. Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ, Atreja A, Ron Y, Swaminath A, Shah S, Hart A, Lakatos PL, Ellul P, Israeli E, Svendsen MN, van der Woude CJ, Katsanos KH, Yun L, Tsianos EV, Nathan T, Abreu M, Dotan I, Lashner B, Brynskov J, Terdiman JP, Higgins PD, Chaparro M, Ben-Horin S. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis. 2012 Nov; 18(11):2026-33.
    View on PubMed
  15. Larsen M, Hills N, Terdiman J. The impact of the quality of colon preparation on follow-up colonoscopy recommendations. Am J Gastroenterol. 2011 Dec; 106(12):2058-62.
    View on PubMed
  16. Lin KK, Velayos F, Fisher E, Terdiman JP. Durability of infliximab dose intensification in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1013-9.
    View on PubMed
  17. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011 Jul 19; 155(2):69-79.
    View on PubMed
  18. Khan O, Blanco A, Conrad P, Gulden C, Moss TZ, Olopade OI, Kupfer SS, Terdiman J. Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol. 2011 Oct; 106(10):1822-7; quiz 1828.
    View on PubMed
  19. Terdiman JP. The prevention of colitis-related cancer by 5-aminosalicylates: an appealing hypothesis that remains unproven. Am J Gastroenterol. 2011 Apr; 106(4):737-40.
    View on PubMed
  20. Day LW, Espey DK, Madden E, Segal M, Terdiman JP. Screening prevalence and incidence of colorectal cancer among American Indian/Alaskan natives in the Indian Health Service. Dig Dis Sci. 2011 Jul; 56(7):2104-13.
    View on PubMed

Go to UCSF Profiles, powered by CTSI